256 related articles for article (PubMed ID: 19006610)
21. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
[TBL] [Abstract][Full Text] [Related]
23. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib for imatinib-resistant GIST.
Joensuu H
Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
[No Abstract] [Full Text] [Related]
27. [Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Shi Y; Liang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):321-5. PubMed ID: 24760637
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M
Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035
[TBL] [Abstract][Full Text] [Related]
30. New paradigms in gastrointestinal stromal tumour management.
Blay JY
Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
[TBL] [Abstract][Full Text] [Related]
31. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD
Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557
[TBL] [Abstract][Full Text] [Related]
32. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
Nilsson B; Nilsson O; Ahlman H
Expert Opin Investig Drugs; 2009 Apr; 18(4):457-68. PubMed ID: 19335275
[TBL] [Abstract][Full Text] [Related]
33. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Guo T; Hajdu M; Agaram NP; Shinoda H; Veach D; Clarkson BD; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2009 Nov; 15(22):6862-70. PubMed ID: 19861442
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
36. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
[TBL] [Abstract][Full Text] [Related]
38. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Heinrich MC; Marino-Enriquez A; Presnell A; Donsky RS; Griffith DJ; McKinley A; Patterson J; Taguchi T; Liang CW; Fletcher JA
Mol Cancer Ther; 2012 Aug; 11(8):1770-80. PubMed ID: 22665524
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]